According to VCBeat, GenAns Biotechnology Co., Ltd. announced on July 30, 2026 that it has successfully completed its Series A financing worth hundreds of millions of RMB. Funds raised in this round will comprehensively accelerate the company’s R&D layout in precise neuromodulation of the nervous system, supporting the development of treatments for severe central nervous system and ophthalmic diseases.

The Series A round was led by Taiping Healthcare Industry Equity Fund, with substantial follow-on investment from funds managed by existing shareholder Huatai Zijin (Jiangsu) Equity Investment Fund. Gaorong Ventures, Fortune Capital, Citic Capital, Biotest BCI Fund and other institutions participated in the financing. Existing investors including Beijing Medical and Health Fund and CoWin Ventures continued to increase their investments. XQ Capital served as the financial advisor for this financing round.

Funds raised from this round will be primarily allocated to advancing clinical validation of the company’s multiple core pipelines, accelerating the R&D of backup pipelines and the progress of dual filings in China and the United States. The capital will also further strengthen the company’s platform capabilities in cutting-edge brain science technologies such as chemogenetics and optogenetics, enabling continuous development of globally innovative drugs that leverage precise neuromodulation for the treatment of intractable brain diseases.

For a long time, central nervous system and ophthalmic diseases have represented deep-water areas and high-barrier tracks for global innovative drug R&D. These conditions feature complex disease mechanisms and high patient heterogeneity, and conventional medicines struggle to precisely modulate aberrant neural circuits. Numerous patients with hereditary retinal disorders, intractable epilepsy, central neuropathic pain and other illnesses continue to suffer from limited treatment options and heavy disease burdens, leaving massive unmet clinical needs.

Drawing on the founding team’s long-standing expertise in fundamental brain science research and translational neuromodulation technologies, GenAns Biotech stands as the world’s only enterprise advancing both chemogenetics and optogenetics neuromodulation technology platforms to develop precision therapies for brain diseases. The company employs delivery vectors to locally deliver engineered photosensitive proteins or chemical receptors to targeted neural circuits, enabling precise, reversible, controllable and on-demand modulation of aberrant neural activity. Evolving beyond conventional "gene replacement strategies" toward a "precision neuromodulation strategy for neural circuits", GenAns redefines intervention paradigms for central nervous system and ophthalmic diseases.

Driven by this strategic focus and the cutting-edge advances from its AI empowerment center, GenAns Biotech has built five core R&D platforms covering molecules, delivery vectors, viral vectors, cellular activity, electrophysiology and functional evaluation. Supported by the company’s robust internal system for non-clinical assessment (pharmacology & efficacy, toxicology, pharmacokinetics and translational medicine) as well as manufacturing process development, GenAns Biotech has established a full-loop capability spanning early drug design, process development, non-clinical evaluation and clinical translation.

Benefiting from the robust translational efficiency of its platforms, the company’s existing pipeline comprehensively targets major indications including retinal disorders, epilepsy and central neuropathic pain. Its backup pipeline is further expanding into high-barrier fields with substantial unmet medical needs such as Parkinson’s disease, major depressive disorder, drug addiction and malignant brain tumors.

GA001 is the flagship pipeline program from GenAns Biotech’s optogenetics platform that has advanced into clinical validation, targeting retinitis pigmentosa (RP), a hereditary blinding eye disease. Around 1.5 million patients worldwide suffer from RP. Most patients have long lacked effective treatment options and endure progressive irreversible vision loss or even total blindness.

GA001 leverages a novel high-sensitivity photosensitive protein independently discovered by the company. It achieves visual function restoration via targeted transduction into retinal ganglion cells. Genotype-independent, this candidate is expected to benefit a broad population of patients with retinitis pigmentosa (RP). Subject data demonstrate that GA001 exhibits favorable safety and efficacy profiles. Multiple subjects with extremely low vision regained the ability to recognize multiple lines on visual acuity charts after treatment, showing therapeutic outcomes superior to published peer-reviewed data of comparable global pipelines.

GA001 has obtained clearance for Phase II clinical trials from the US FDA, as well as Orphan Drug Designation (ODD) and Fast Track Designation (FTD). In China, the program has secured Phase I clinical trial approval from CDE and officially initiated registrational clinical trials this month. The pipeline has been honored among the Top 10 Scientific and Technological Achievements at the Zhongguancun Forum, listed as an Internationally Leading Scientific and Technological Achievement by the Ministry of Industry and Information Technology, and recognized as an Innovative Case of Technology Empowering Persons with Disabilities by the China Disabled Persons' Federation.

There are approximately 50 million epilepsy patients worldwide, among whom roughly 30% suffer from drug-resistant epilepsy. GA002 targets drug-resistant focal epilepsy, a condition affecting around 2 million patients in China with tremendous unmet clinical needs. The product enables targeted expression of engineered inhibitory receptors developed in-house within epileptic foci, which can be activated on demand by specific ligands to achieve precise and reversible suppression of abnormal electrical discharges. It is expected to offer a novel therapeutic option for patients with drug-resistant epilepsy and those who cannot be treated via surgical lesion resection.

GA002 represents the world’s first precision therapy for drug-resistant focal epilepsy to advance into human clinical validation, and GA008 is recognized as the world’s first precision therapy for intractable central neuropathic pain to enter human clinical validation. An estimated 15 million to 20 million patients globally suffer from intractable central neuropathic pain, including post-stroke pain, spinal cord injury-related pain and other indications with limited efficacy from existing therapies. Differing from the disease intervention mechanisms of conventional analgesics, this pipeline is poised to deliver an innovative treatment option for intractable central neuropathic pain. Data indicate that GA008 can significantly relieve refractory pain while alleviating accompanying symptoms such as anxiety, depression and sleep disorders. It also demonstrates a favorable safety profile with no addiction risk and no impairment of cognitive function.

In addition, backed by the continuous accumulation of multiple early research data, the company will further expand its optogenetics and chemogenetics technologies to broader clinical scenarios including Parkinson’s disease, major depressive disorder, drug addiction and malignant brain tumors via dual China-U.S. filing strategies, accelerating the global clinical validation and translation of China-originated brain science technologies.